Safety of physiological testosterone therapy in women: Lessons from Female-to-Male Transsexuals (FMT) treated with pharmacological testosterone therapy

Journal of Sexual Medicine

Volumn 7, Issue 11, 2010, Pages 3758-3764

  Traish, Abdulmaged M ^a   Gooren, Louis J ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adverse Effects; Breast Cancer; Female to Male Transsexual; Safety of Testosterone; Sexual Dysfunction; Testosterone

Indexed keywords

TESTOSTERONE;

ANDROGEN THERAPY; ARTICLE; BREAST; BREAST CANCER; DRUG SAFETY; ENDOMETRIUM; FEMALE; HORMONE ACTION; HUMAN; MEDICAL LITERATURE; OVARY; PRIORITY JOURNAL; PUBLICATION; SEXUAL DYSFUNCTION; TRANSSEXUALISM; VASCULAR DISEASE;

EID: 78049471739     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01962.x     Document Type: Article

References (57)

1. Schover LR. Androgen therapy for loss of desire in women: Is the benefit worth the breast cancer risk? Fertil Steril 2008;90:129-40.
2. Basson R. Pharmacotherapy for women's sexual dysfunction. Expert Opin Pharmacother 2009;10:1631-48.
3. Basson R. Testosterone for low libido. N Engl J Med 2009;360:728.
4. Basson R. Testosterone supplementation to improve women's sexual satisfaction: Complexities and unknowns. Ann Intern Med 2008;148:620-1.
5. Basson R, Wierman ME, Van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J Sex Med 2010;7:314-26.
6. Wierman ME, Nappi RE, Avis N, Davis SR, Labrie F, Rosner W, Shifren JL. Endocrine aspects of women's sexual function. J Sex Med 2010;7:561-85.
7. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N. Androgen therapy in women: An Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006;91:3697-710.
8. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: Effects and risks of administration of androgens to females. J Sex Med 2008;5:765-76.
9. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: Extensive personal experience. J Clin Endocrinol Metab 2008;93:19-25.
10. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008;159:197-202.
11. Pache TD, Chadha S, Gooren LJ, Hop WC, Jaarsma KW, Dommerholt HB, Fauser BC. Ovarian morphology in long-term androgen-treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome? Histopathology 1991;19:445-52.
12. Jacobeit JW, Gooren LJ, Schulte HM. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Eur J Endocrinol 2009;161:795-8.
13. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J, APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359:2005-17.
14. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: Results from the INTIMATE NM1 Study. Menopause 2006;13:770-9.
15. Davis SR, Van Der Mooren MJ, Van Lunsen RH, Lopes P, Ribot C, Rees M, Moufarege A, Rodenberg C, Buch A, Purdie DW. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Menopause 2006;13:387-96.
16. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-9.
17. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-33.
18. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, Rodenberg CA, Wekselman K, Casson P. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005;105:944-52.
19. Van Staa TP, Sprafka JM. Study of adverse outcomes in women using testosterone therapy. Maturitas 2009;62:76-80.
20. Braunstein GD. Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007;88:1-17.
21. Shufelt CL, Braunstein GD. Testosterone and the breast. Menopause Int 2008;14:117-22.
22. Shufelt CL, Braunstein GD. Safety of testosterone use in women. Maturitas 2009;63:63-6.
23. Basaria S, Dobs AS. Safety and adverse effects of androgens: How to counsel patients. Mayo Clin Proc 2004;79(4 suppl):S25-32.
24. Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon J. Safety and tolerability of the transdermal testosterone patch for up to 4 years in surgically menopausal women on estrogen/progestin therapy. St Petersburg, FL: Program of the International Society for the Study of Women's Sexual Health (ISSWSH); 2010:(Abstract # 24).
25. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005;19:CD004509.
26. Jacobeit JW, Gooren LJ, Schulte HM. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. J Sex Med 2007;4:1479-84.
27. Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab 2007;92:3470-345.
28. Meriggiola MC, Armillotta F, Costantino A, Altieri P, Saad F, Kalhorn T, Perrone AM, Ghi T, Pelusi C, Pelusi G. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. J Sex Med 2008;5:2442-53.
29. Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf) 2003;58:562-71.
30. Berra M, Armillotta F, D'Emidio L, Costantino A, Martorana G, Pelusi G, Meriggiola MC. Testosterone decreases adiponectin levels in female to male transsexuals. Asian J Androl 2006;8:725-9.
31. Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, Casadio P, Ghi T, Pelusi G, Pelusi C, Meriggiola MC. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med 2009;6:3193-200.
32. Futterweit W, Deligdisch L. Effects of androgens on the ovary. Fertil Steril 1986;46:343-45.
33. Burgess HE, Shousha S. An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: A comparison with normal female breast and male breast showing gynaecomastia. J Pathol 1993;170:37-43.
34. Slagter MH, Gooren LJ, Scorilas A, Petraki CD, Diamandis EP. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J Histochem Cytochem 2006;54:905-10.
35. Elbers JM, Asscheman H, Seidell JC, Megens JA, Gooren LJ. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab 1997;82:2044-7.
36. Goh HH, Ratnam SS. Effects of hormone deficiency, androgen therapy and calcium supplementation on bone mineral density in female transsexuals. Maturitas 1997;26:45-52.
37. Turner A, Chen TC, Barber TW, Malabanan AO, Holick MF, Tangpricha V. Testosterone increases bone mineral density in female-to-male transsexuals: A case series of 15 subjects. Clin Endocrinol (Oxf) 2004;61:560-6.
38. Lips P, Van Kesteren PJ, Asscheman H, Gooren LJ. The effect of androgen treatment on bone metabolism in female-to-male transsexuals. J Bone Miner Res 1996;11:1769-73.
39. Van Kesteren PJM, Asscheman H, Megens JAJ, Gooren LJG. Mortality and morbidity in transsexuals subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997;47:337-42.
40. Goh HH, Loke DF, Ratnam SS. The impact of long-term testosterone replacement therapy on lipid and lipoprotein profiles in women. Maturitas 1995;21:65-70.
41. Emi Y, Adachi M, Sasaki A, Nakamura Y, Nakatsuka M. Increased arterial stiffness in female-to-male transsexuals treated with androgen. J Obstet Gynaecol Res 2008;34:890-7.
42. Asscheman H, Gooren LJG, Eklund PLE. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism 1989;38:869-73.
43. Asscheman H, Giltay EJ, Megens JAJ, Gooren LJG. Long term mortality in hormone-treated transsexuals. Endocrine Society Abstract 2009.
44. Traish A, Fetten K, Miner M, Hansen M, Guay A. Testosterone and risk of breast cancer: Appraisal of existing evidence. Horm Mol Biol Clin Invest 2010;2:177-90.
45. Sapino A, Pietribiasi F, Godano A, Bussolati G. Effect of long-term administration of androgens on breast tissues of female-to-male transsexuals. Ann N Y Acad Sci 1990;586:143-5.
46. Futterweit W, Green G, Tarlin N, Dunaif A. Chronic high-dosage androgen administration to ovulatory women does not alter adrenocortical steroidogenesis. Fertil Steril 1992;58:124-8.
47. Fanchin R, Dubost G, Colau JC, Brémont-Weil C, Frydman R, Ayoubi JM, Grynberg M. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 2010;20:553-8.
48. Burcombe RJ, Makris A, Pittam M, Finer N. Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. Breast 2003;12:290-3.
49. Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab 2008;93:1408-11.
50. Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: A systematic review and meta-analyses. Clin Endocrinol (Oxf) 2010;72:1-10.
51. Traish AM, Feeley RJ, Guay AT. Testosterone therapy in women with gynecological and sexual disorders: a triumph of clinical endocrinology from 1938 to 2008. J Sex Med 2009;6:334-51.
52. Kingsberg S. Testosterone treatment for hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2007;4(suppl 3):227-34.
53. Davis SR, Hirschberg AL, Wagner LK, Lodhi I, Von Schoultz B. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J Clin Endocrinol Metab 2009;94:4907-13.
54. Davis SR. Should women receive androgen replacement therapy, and if so, how? Clin Endocrinol (Oxf) 2010;72:149-54.
55. Davis SR. Testosterone for low libido in postmenopausal women not using systemic oestrogen therapy. Med J Aust 2009;191:134-5.
56. Davis SR, Wolfe R, Farrugia H, Ferdinand A, Bell RJ. The incidence of invasive breast cancer among women prescribed testosterone for low libido. J Sex Med 2009;6:1850-6.
57. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 2008;61:17-26.